Low Indeterminate Rates Associated With Use of the QuantiFERON-TB Gold In-Tube Test in Children With Inflammatory Bowel Disease on Long-term Infliximab.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Inflammatory Bowel Diseases

• Publication date

  2018-03-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ibd/izx077PMID 29562270
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of false-positive QuantiFERON-TB Gold In-Tube assays by repeat testing in HIV-infected patients at low risk for tuberculosis.

  2012cited by this paper
• Challenges of interferon-γ release assay conversions in serial testing of health-care workers in a TB control program.

  2012cited by this paper
• Factors Associated with the Performance of a Blood-Based Interferon-γ Release Assay in Diagnosing Tuberculosis

  2012cited by this paper
• Association of age with the level of response in the QuantiFERON-TB Gold In-Tube assay for children with active tuberculosis.

  2011cited by this paper
• Prednisolone treatment affects the performance of the QuantiFERON gold in‐tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection

  2011cited by this paper
• QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States

  2011cited by this paper
• Is tuberculin skin testing reliable during anti-tumor necrosis factor-alfa therapy? A case report and review of the literature.

  2011cited by this paper
• Within-Subject Variability of Mycobacterium tuberculosis-Specific Gamma Interferon Responses in German Health Care Workers

  2011cited by this paper
• Factors impacting the results of interferon‐&ggr; release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases

  2011cited by this paper
• The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

  2010cited by this paper
• Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers

  2010cited by this paper
• Performance of tests for latent tuberculosis in different groups of immunocompromised patients.

  2009cited by this paper
• QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases

  2009cited by this paper
• Latent Tuberculosis Diagnosis in Children by Using the QuantiFERON-TB Gold In-Tube Test

  2009cited by this paper
• Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy.

  2008cited by this paper
• Comparison of Interferon-Gamma Release Assay Versus Tuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease

  2008cited by this paper
• Brief Communication: Characteristics of Spontaneous Cases of Tuberculosis Associated with Infliximab

  2007cited by this paper
• Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

  2006cited by this paper
• Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.

  2006cited by this paper
• BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.

  2005cited by this paper
• Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

  2005cited by this paper
• BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment

  2005cited by this paper
• Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

  2004cited by this paper
• High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy.

  2004cited by this paper
• Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease

  2001cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

  2001cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

  2001cited by this paper
• T lymphopaenia in relation to body mass index and TNF‐α in human obesity: adequate weight reduction can be corrective

  2001cited by this paper
• Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection.

  1998cited by this paper
• An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

  1993cited by this paper

• Risk of tuberculosis in children with rheumatologic diseases treated with biological agents: A cross-sectional cohort study

  2023cites this paper
• Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management

  2022cites this paper
• Tuberculosis and TNF-α inhibitors in children: how to manage a fine balance

  2020cites this paper
• Risk Factors for Indeterminate Interferon-Gamma Release Assay for the Diagnosis of Tuberculosis in Children—A Systematic Review and Meta-Analysis

  2019cites this paper
• Performance of Interferon-Gamma Release Assays for Tuberculosis Screening in Pediatric Inflammatory Bowel Disease.

  2019cites this paper